Market Closed -
Hong Kong S.E.
04:09:00 2024-05-03 am EDT
|
5-day change
|
1st Jan Change
|
0.025
HKD
|
-13.79%
|
|
-3.85%
|
-54.55%
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Capitalization
1 |
2,479
|
1,199
|
280.8
|
192.4
|
110.2
|
151.4
|
Enterprise Value (EV)
1 |
3,120
|
2,122
|
1,235
|
1,036
|
932.9
|
971.9
|
P/E ratio
|
17.4
x
|
-1.22
x
|
-0.44
x
|
-0.53
x
|
-0.73
x
|
-2.27
x
|
Yield
|
1.83%
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
4.1
x
|
2.1
x
|
0.77
x
|
0.87
x
|
0.49
x
|
0.73
x
|
EV / Revenue
|
5.16
x
|
3.71
x
|
3.38
x
|
4.67
x
|
4.11
x
|
4.69
x
|
EV / EBITDA
|
10.9
x
|
-32.4
x
|
-12.7
x
|
-19.6
x
|
-17.3
x
|
26.9
x
|
EV / FCF
|
-20.5
x
|
-24.6
x
|
3.04
x
|
-1.4
x
|
5.78
x
|
3.95
x
|
FCF Yield
|
-4.88%
|
-4.07%
|
32.9%
|
-71.4%
|
17.3%
|
25.3%
|
Price to Book
|
2.27
x
|
5.62
x
|
-1.64
x
|
11.8
x
|
-0.52
x
|
-0.63
x
|
Nbr of stocks (in thousands)
|
1,558,577
|
1,606,463
|
1,904,635
|
1,904,635
|
1,904,635
|
1,904,635
|
Reference price
2 |
1.591
|
0.7464
|
0.1475
|
0.1010
|
0.0579
|
0.0795
|
Announcement Date
|
4/27/18
|
4/29/19
|
5/14/20
|
4/30/21
|
5/30/22
|
4/27/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net sales
1 |
604.8
|
571.5
|
366
|
221.7
|
226.7
|
207.1
|
EBITDA
1 |
286.9
|
-65.43
|
-97.2
|
-52.76
|
-53.79
|
36.08
|
EBIT
1 |
255.7
|
-99.36
|
-125.6
|
-73.03
|
-89.99
|
18.92
|
Operating Margin
|
42.27%
|
-17.38%
|
-34.31%
|
-32.93%
|
-39.7%
|
9.14%
|
Earnings before Tax (EBT)
1 |
226.4
|
-562
|
-583.5
|
-200.3
|
-148.8
|
-54.3
|
Net income
1 |
165.2
|
-957.7
|
-587.6
|
-357.6
|
-149.5
|
-66.4
|
Net margin
|
27.31%
|
-167.56%
|
-160.56%
|
-161.28%
|
-65.96%
|
-32.07%
|
EPS
2 |
0.0912
|
-0.6116
|
-0.3331
|
-0.1895
|
-0.0791
|
-0.0350
|
Free Cash Flow
1 |
-152.3
|
-86.28
|
406.4
|
-740
|
161.5
|
246.2
|
FCF margin
|
-25.17%
|
-15.1%
|
111.04%
|
-333.72%
|
71.24%
|
118.88%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
682.44%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
0.0291
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/27/18
|
4/29/19
|
5/14/20
|
4/30/21
|
5/30/22
|
4/27/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net Debt
1 |
640
|
923
|
955
|
844
|
823
|
821
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
2.231
x
|
-14.1
x
|
-9.821
x
|
-15.99
x
|
-15.29
x
|
22.74
x
|
Free Cash Flow
1 |
-152
|
-86.3
|
406
|
-740
|
162
|
246
|
ROE (net income / shareholders' equity)
|
17.1%
|
-58.9%
|
-200%
|
-308%
|
160%
|
29.3%
|
ROA (Net income/ Total Assets)
|
6%
|
-2.49%
|
-3.9%
|
-2.95%
|
-5%
|
1.21%
|
Assets
1 |
2,751
|
38,454
|
15,071
|
12,118
|
2,992
|
-5,507
|
Book Value Per Share
2 |
0.7000
|
0.1300
|
-0.0900
|
0.0100
|
-0.1100
|
-0.1300
|
Cash Flow per Share
2 |
0.0900
|
0.0500
|
0.0100
|
0
|
0
|
0
|
Capex
1 |
9.73
|
11.9
|
36
|
23.8
|
0.65
|
4.49
|
Capex / Sales
|
1.61%
|
2.09%
|
9.85%
|
10.75%
|
0.28%
|
2.17%
|
Announcement Date
|
4/27/18
|
4/29/19
|
5/14/20
|
4/30/21
|
5/30/22
|
4/27/23
|
|
1st Jan change
|
Capi.
|
---|
| -54.55% | 8.45M | | +19.98% | 43.48B | | +20.67% | 22.65B | | +14.56% | 14.73B | | +44.72% | 12.04B | | -8.37% | 7.08B | | -0.05% | 6.79B | | -8.87% | 5.73B | | +11.90% | 5.47B | | -2.27% | 4.81B |
Generic Pharmaceuticals
|